VEGFA and ischemia: Treatment included administration of intravitreal antivascular endothelial growth factor (VEGF) in 1 (6.6%) eye, the use of a sustained-release intravitreal dexamethasone implant in 7 (46.6%) eyes, whereas 2 (13.3%) eyes required retinal laser photocoagulation due to extensive ischemia, not in association with anti-VEGF injections.